Jagsonpal Pharmaceuticals Ltd.
Snapshot View

171.95 +3.75 ▲2.2%

26 July 2021, 04:00:00 P.M.
Volume: 24,490

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.jagsonpal.com
Financial Indicators
Market Cap 450.47 Cr.
Earnings per share (EPS) 6.51 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 26.41 Trailing Twelve Months Ending 2021-03
Industry PE 35.17 Trailing Twelve Months Ending 2021-03
Book Value / Share 43.55 Trailing Twelve Months Ending 2021-03
Price to Book Value 3.95 Calculated using Price: 171.95
Dividend Yield 0.58 Period Ending 2020-03
No. of Shares Subscribed 2.62 Cr. 26,198,000 Shares
FaceValue 5
Company Profile

In 1964 Jagsonpal started from humble beginnings with Jagmohan S. Kochhar operating a chemists shop in Delhi. Soon he expanded into making formulations. Mr. Kochhar’s vision was to spread health and healing in India on a larger scale. He was at the helm of the company from its inception, through the startup phase. Even though Jagsonpal was a small business at the time, his vision was to create one of India’s premiere pharmaceutical companies.

In 1978, Fourteen years later, the company had outgrown the startup phase and was incorporated as a private limited company. Jagsonpal was now a fast growing pharmaceutical company. The firm was committed to healing India with quality pharmaceutical products and had its eyes firmly set on becoming one of the country’s leading pharmaceutical companies.

In 1986 Jagsonpal went public on the BSE. This was the first time the firm had tapped the capital markets.

In 1994 the company was listed on the NSE. This trait of not being content with the status quo has become a core part of Jagsonpal’s company culture. Commitment to growth is ingrained in the very soul of the company and this is reflected in the Jagsonpal’s current aggressive growth strategy.

Jagsonpal is among India’s premiere pharmaceutical companies. Jagsonpal has substantial research and development, manufacturing, marketing and distribution facilities. An impeccable track record of growth and profitability spanning over 4 decades, makes Jagsonpal an ideal company to partner with. The company specializes in developing and manufacturing bulk drugs and pharmaceutical formulations. The firm is committed to sustainable growth and is aggressively pursuing growth through market penetration, market expansion and multi-national expansion.

The firm’s objective is to increase market share and become a dominant player in the Indian Pharmaceutical Industry.Jagsonpal has an expanding international portfolio of affiliates, joint ventures and representative offices across the globe making it a truly international operation.

Product range of the company includes:

  • Dextropropoxyphene
  • Tolnaftate 
  • Indocap SR
  •  Sterile Unipacks 
  • Thiopental sodium

Upcoming products:

  • Nandralone laurate
  • Ethisterone
  • Norgestimate
  • Estradiol
  • Estradiol benzoate
  • Estradiol valerate
  • Estradiol phenylpropionate
  • Mifepristone
  • Finasteride/dutasteride
  • Budesonide
  • Cyproterone/acetate
  • Mestranol
  • Llynestrenol
  • Norethisterone enanthate
  • Estriol base and succinate
  • Ethinyl estradiol
  • Estrone

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+2.23%
1 Week
+0.67%
1 Month
+10.01%
3 Month
+73.95%
6 Month
+132.05%
1 Year
+335.32%
2 Year
+655.82%
5 Year
+347.20%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 9.07 2.15 2.47 1.35 3.65 12.32 -12.01 7.72 7.88
Return on Capital Employed (%) 12.68 6.42 6.57 4.93 7.32 14.26 -10.52 9.80 9.53
Return on Assets (%) 5.09 1.19 1.37 0.75 2.08 7.86 -8.48 5.43 5.57

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 98 98 99 95 98 110 98 104 111
Non Curr. Liab. 4 5 4 4 4 3 3 3 3
Curr. Liab. 53 50 54 55 57 29 29 28 33
Minority Int.
Equity & Liab. 156 153 156 154 159 143 130 136 147
Non Curr. Assets 65 66 65 58 58 33 35 38 52
Curr. Assets 91 87 91 96 101 110 95 98 95
Misc. Exp. not W/O
Total Assets 156 153 156 154 159 143 130 136 147

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 177 166 144 138 143 144 127 167 159
Other Income 0 0 0 0 1 0 0 1 3
Total Income 177 167 144 138 144 144 127 168 161
Total Expenditure -160 -156 -133 -129 -132 -138 -138 -157 -150
PBIDT 17 10 11 9 12 6 -11 11 11
Interest -4 -5 -5 -4 -5 -3 -1 -1 -1
Depreciation -3 -3 -3 -3 -3 -2 0 -1 -1
Taxation -3 -1 0 -1 -1 -3 0 -2 -2
Exceptional Items 13
PAT 7 2 2 1 3 12 -12 7 8

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 7 12 8 4 9 -3 -2 31 11
Cash Fr. Inv. -5 -3 -1 0 -2 41 -3 -1 -11
Cash Fr. Finan. 0 -8 -4 -1 -6 -34 -1 -6 -1
Net Change 3 0 2 2 1 5 -6 24 0
Cash & Cash Eqvt 10 10 13 15 16 20 15 39 38

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 70.33 70.34 70.34 70.34 70.34 70.34 70.34 70.34 70.34
Public 29.67 29.66 29.66 29.66 29.66 29.66 29.66 29.66 29.66
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Mon, 19 Jul 2021
Shareholding for the Period Ended June 30 2021
Jagsonpal Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here
Wed, 14 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0000
Name of the Signatory :- NANDITA SINGH
Designation :- Company Secretary and Compliance Officer
Mon, 12 Jul 2021
Clarification sought from Jagsonpal Pharmaceuticals Ltd
The Exchange has sought clarification from Jagsonpal Pharmaceuticals Ltd on July 12 2021 with reference to Movement in Volume.

The reply is awaited.

Technical Scans View Details

Fri, 23 Jul 2021
Stock Outperforming Benchmark Index in both 1 Week and 3 Month Stock Outperforming Benchmark Index in both 1 Week and 3 Month
Stock Outperforming Sectoral Index in both 1 Week and 3 Month Stock Outperforming Sectoral Index in both 1 Week and 3 Month
Strongly Outperforming Benchmark Index Strongly Outperforming Benchmark Index
Decreasing Relative Strength - Benchmark index Decreasing Relative Strength - Benchmark index
Strongly Outperforming Sectoral Index Strongly Outperforming Sectoral Index

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 166,513.85 703.40 +1.4%
Divi's Laboratories Ltd. 128,088.59 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. 90,175.51 5,411.25 -0.2%
Cipla Ltd. 76,510.04 950.55 +0.3%
Cadila Healthcare Ltd. 62,965.29 605.55 -1.6%
Aurobindo Pharma Ltd. 56,484.48 952.95 -1.1%
Apollo Hospitals Enterprise Ltd. 56,291.69 4,100.95 +4.7%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 57.34 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 64.55 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.21 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 31.81 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 29.51 605.55 -1.6%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.59 952.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 374.38 4,100.95 +4.7%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.58 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 13.78 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.15 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 4.17 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.85 605.55 -1.6%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.58 952.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.25 4,100.95 +4.7%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 0.18 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 605.55 -1.6%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 952.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,100.95 +4.7%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 10.09 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 605.55 -1.6%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 952.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,100.95 +4.7%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 12.53 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 605.55 -1.6%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 952.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,100.95 +4.7%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 17,131.99 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 605.55 -1.6%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 952.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,100.95 +4.7%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 1,546.98 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 605.55 -1.6%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 952.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,100.95 +4.7%